SCHEMBL4112426

SCHEMBL4112426

CCOC(=O)c1c(NS(C)(=O)=O)nn2c(-c3ccc(C(F)(F)F)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.41
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PKM P14618 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 1/20 0.36
PDE4B Q07343 1/20 0.36
TSHR P16473 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
FOS P01100 1/20 0.35
JUN P05412 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2086689 0.91 TP53 (0.43) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2084824 0.88 GPR119 (0.42) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2084189 0.88 GPR119 (0.43) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2087297 0.87 GPR119 (0.46) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2083460 0.86 GPR119 (0.43) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2083585 0.86 GPR119 (0.45) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL4120345 0.86 GPR119 (0.41) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL4129331 0.85 GPR119 (0.41) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2085513 0.85 GPR119 (0.46) GPR119MAPTKDM4EALDH1A1HPGD
SCHEMBL2085685 0.84 GPR119 (0.43) GPR119MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD GPR119 2137/4885MAPT 4568/4885KDM4E 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.